Literature DB >> 27826566

Variations in mRNA and protein levels of Ikaros family members in pediatric T cell acute lymphoblastic leukemia.

Julie L Mitchell1, Thomas M Yankee2.   

Abstract

BACKGROUND: Pediatric T cell acute lymphoblastic leukemia (T-ALL) is a highly heterogeneous disease in which the cells share phenotypic characteristics with normal human thymocytes. The Ikaros family of transcription factors includes five members that are required for normal T cell development and are implicated in leukemogenesis. The goal of this work was to correlate the pattern of expression of Ikaros family members with the phenotype of the T-ALL cells.
METHODS: We obtained twenty-four samples from pediatric T-ALL patients and used multi-parameter flow cytometry to characterize each sample, comparing the phenotype of the leukemic cells with normal human thymocytes. Then, we defined the expression levels of each Ikaros family member to determine whether the mRNA levels or splicing or protein levels were similar to the normal patterns seen during human T cell development.
RESULTS: Multi-parameter analysis of the phenotype of T-ALL cells revealed that each patient's cells were unique and could not be readily correlated with stages of T cell development. Similarly, the pattern of Ikaros expression varied among patients. In most patients, Ikaros mRNA was the dominant family member expressed, but some patients' cells contained mostly Helios, Aiolos, or Eos mRNA. Despite that most patients had elevated mRNA levels of Ikaros family members and unique patterns of mRNA splicing, most patients had significantly reduced protein levels of Ikaros and Aiolos.
CONCLUSIONS: Our analysis of the cell phenotype and Ikaros expression levels in T-ALL cells revealed the extent of heterogeneity among patients. While it is rarely possible to trace leukemic cells to their developmental origin, we found distinct patterns of Ikaros family mRNA levels in groups of patients. Further, mRNA and protein levels of Ikaros and Aiolos did not correlate, indicating that mRNA and protein levels are regulated via distinct mechanisms.

Entities:  

Keywords:  Aiolos; Helios; Ikaros; pediatric T cell acute lymphoblastic leukemia (pediatric T-ALL)

Year:  2016        PMID: 27826566      PMCID: PMC5075847          DOI: 10.21037/atm.2016.09.29

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  67 in total

Review 1.  Transcriptional control of t lymphocyte differentiation.

Authors:  F J Staal; F Weerkamp; A W Langerak; R W Hendriks; H C Clevers
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

2.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

3.  Critical function of Ikaros in controlling Aiolos gene expression.

Authors:  Ata Ghadiri; Marianne Duhamel; Aarne Fleischer; Andreas Reimann; Frederic Dessauge; Angelita Rebollo
Journal:  FEBS Lett       Date:  2007-03-20       Impact factor: 4.124

4.  ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenes.

Authors:  Adam A Margolin; Teresa Palomero; Pavel Sumazin; Andrea Califano; Adolfo A Ferrando; Gustavo Stolovitzky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-31       Impact factor: 11.205

5.  Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin.

Authors:  K Hahm; B S Cobb; A S McCarty; K E Brown; C A Klug; R Lee; K Akashi; I L Weissman; A G Fisher; S T Smale
Journal:  Genes Dev       Date:  1998-03-15       Impact factor: 11.361

6.  Transgenic expression of Helios in B lineage cells alters B cell properties and promotes lymphomagenesis.

Authors:  Sinisa Dovat; Encarnacion Montecino-Rodriguez; Valerie Schuman; Michael A Teitell; Kenneth Dorshkind; Stephen T Smale
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

7.  Characterization of CD4+ single positive cells that lack CD3 in the human thymus.

Authors:  Y Takeuchi; Y Fujii; M Okumura; K Inada; K Nakahara; H Matsuda
Journal:  Cell Immunol       Date:  1993-10-15       Impact factor: 4.868

8.  Ikaros regulates Notch target gene expression in developing thymocytes.

Authors:  Sheila Chari; Susan Winandy
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

10.  High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.

Authors:  R P Kuiper; E F P M Schoenmakers; S V van Reijmersdal; J Y Hehir-Kwa; A Geurts van Kessel; F N van Leeuwen; P M Hoogerbrugge
Journal:  Leukemia       Date:  2007-04-19       Impact factor: 11.528

View more
  2 in total

1.  T-ALL can evolve to oncogene independence.

Authors:  Hesham Abdulla; Anh Vo; Benjamin J Shields; Tenae J Davies; Jacob T Jackson; Raed Alserihi; Elizabeth M Viney; Tin Wong; Feng Yan; Nicholas C Wong; Lisa Demoen; David J Curtis; Warren S Alexander; Pieter Van Vlierberghe; Ross A Dickins; Matthew P McCormack
Journal:  Leukemia       Date:  2021-01-22       Impact factor: 11.528

2.  A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Authors:  Irena Misiewicz-Krzeminska; Luis Antonio Corchete; Elizabeta A Rojas; Joaquín Martínez-López; Ramón García-Sanz; Albert Oriol; Joan Bladé; Juan-José Lahuerta; Jesús San Miguel; María-Victoria Mateos; Norma C Gutiérrez
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.